Table 3.
Regular use of Aspirin by Self-Reported Indications and Risk of Ovarian Cancer in the HOPE study
| No. Cases | No. Controls | OR (95% CI)a | |
|---|---|---|---|
| Nonusers b | 623 | 1186 | 1.00 |
| Regular usersc by indicationsd | |||
| Prevention for CVD | 159 | 392 | 0.72 (0.57–0.97) |
| Arthritis/bursitis, rheumatism | 44 | 93 | 0.80 (0.53–1.21) |
| Headache | 51 | 94 | 1.04 (0.71–1.52) |
| Other pain or injuries | 50 | 75 | 1.27 (0.85–1.90) |
a
ORs and p-values were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births, duration of oral contraception use (years), body mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.
b
Non-user: women who indicated that they had not used aspirin ≥ 2 tablets/week for ≥ 6 months (“minimal level”). Reference category.
c
Regular user: women who indicated that they had used aspirin ≥ 2 tablets/week for ≥ 6 months
d
If patients used aspirin for different major indications before the reference date, each episode was counted separately